Aloe Blacc says he is building a cancer drug company without fundraising yet

In short: Singer-songwriter Aloe Blacc says he is building a biotech company to work on pancreatic cancer, and he is choosing not to raise outside money yet.

What happened

Aloe Blacc, a Grammy-nominated musician, spoke on TechCrunch’s Equity podcast about his move into biotech, which is the industry that develops new medicines.

He said his interest grew after he got COVID even though he was vaccinated and boosted. He tried to fund research directly, but learned that in medicine you cannot simply donate money and expect a treatment to move forward. Regulators (government health agencies that check safety) usually expect a real plan for how a drug could be tested, made, and delivered.

Blacc said he is now bootstrapping, meaning he is paying for the work himself instead of taking investment money. His company is focused on a drug platform aimed at pancreatic cancer. TechCrunch notes the disease kills about 90% of patients.

He also said he is intentionally waiting to fundraise from his network until there are peer-reviewed papers. Peer review is when other scientists check research before it is treated as credible, like having independent inspectors verify the work.

Why it matters

This is a reminder that health research runs on proof and process, not personal influence. For regular people, it helps explain why new drugs can take so long and why promising ideas still need published results and clinical trials (carefully controlled tests in people) before they can become real treatments.

Source: TechCrunch AI